Juvenile Rheumatoid Arthritis News and Research

RSS

Juvenile rheumatoid arthritis (JRA) is a severe autoimmune disorder that causes both painful and disabling arthritis and ocular manifestations which can result in blindness.

Comparative genomic analysis between systemic juvenile rheumatoid arthritis and type 1 diabetes

Shared genetic markers and immune system involvement in sJRA and T1D.

15 Sep 2023

Hospitalization risk high for IBD patients with incomplete COVID-19 vaccinations

The Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA) are bringing together the inflammatory bowel disease (IBD) care community for the fifth annual Crohn's & Colitis Congress®, taking place virtually Jan. 20 through 22, 2022.

21 Jan 2022

UTHealth tests arthritis drug's effect on COVID-19-induced cytokine storm

A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston.

22 Jun 2020

DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune system could be used to treat cancer or predict outcomes for patients.

18 Feb 2016

Hip replacement procedure alleviates pain, improves function in young JIA patients

Hip replacement is often performed in patients with juvenile arthritis when their joints have been severely damaged by the disease.

25 Mar 2015

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.

1 Jul 2014

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Parenting stress among caregivers of children with chronic illness: A systematic review

The extra demands on parents of chronically ill children cause stress that affects the whole family, according to a systematic review conducted by Case Western Reserve University researchers that also explored what factors in the child's care most contribute to the added strain.

19 Sep 2013

Study provides first genomic characterization of remission in juvenile rheumatoid arthritis patients

More children with juvenile rheumatoid arthritis are experiencing remission of their symptoms, thanks to new biological therapies, but the remission is not well-understood. A new study published today in Arthritis Research & Therapy provides the first genomic characterization of remission in juvenile rheumatoid arthritis patients.

30 Aug 2013

Study: Total knee replacements in younger patients with juvenile arthritis last for 10 years

When you think of knee replacement surgery, you generally envision an older adult with painful arthritis. But the procedure is also used for younger patients with juvenile idiopathic arthritis whose joints have been severely damaged by the disease. Because the surgery in younger patients is relatively rare, little data exist on the longevity of knee replacements in JIA patients.

19 Mar 2013

DMARDs appear to be more effective for children with arthritis

Medications known as disease-modifying anti-rheumatic drugs, or DMARDs, appear to be more effective than other treatments for children with arthritis, but there is not enough evidence to support one kind of DMARD over another, according to a new report from HHS' Agency for Healthcare Research and Quality.

28 Sep 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Scientists identify potential target for reversing deadly blood infection sepsis

By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.

13 Jun 2011

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

While lab tests and imaging can sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical examination and thorough patient history are the most valuable tools in identifying this disease. According to a new literature review from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the rate of false positives in laboratory evaluations and imaging studies meant to screen for juvenile arthritis makes their value limited.

3 Mar 2011

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.

15 Oct 2010

Susceptibility to Behcet's disease associated with genes involved in body's immune response

Researchers with the National Institutes of Health have found susceptibility to Behcet's disease, a painful, inflammatory condition, to be associated with genes involved in the body's immune response.

14 Jul 2010

U.S. study finds improved mortality outcomes for children with rheumatic diseases

A recent study by researchers from the Cleveland Clinic found that the overall mortality rate in the U.S. for all pediatric patients with rheumatic diseases was not worse than the age and sex-adjusted population.

28 Jan 2010

Study affirms effectiveness of medication for juvenile rheumatoid arthritis

Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease that strikes children between the ages of newborn to 16 years. All children with JRA have joint pain, stiffness, and swelling and some also have fever and skin rashes.

9 May 2008

Latona acquires patent rights and orphan drug status to drug compound for rheumatoid arthritis

Latona Life Sciences Inc. announced today that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked "Oralgam," for the treatment of Juvenile and Adult Rheumatoid Arthritis.

24 Apr 2008